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Abstract
Background: Relatively few studies have examined survival by pharmacotherapy level and the effects of patient 
characteristics on mortality by pharmacotherapy level in older chronic respiratory disease (CRD) patients. This study 
aimed to investigate these issues in older (≥ 65) CRD patients in Western Australia.
Methods: We identified 108,312 patients ≥ 65 years with CRD during 1992-2006 using linked medical, pharmaceutical, 
hospital and mortality databases held by the Commonwealth and State governments. Pharmacotherapy classification 
levels were designed by a clinical consensus panel. Cox regression was used to investigate the study aim.
Results: Patients using only short acting bronchodilators experienced similar, but slightly worse survival than patients 
in the highest pharmacotherapy level group using high dose inhaled corticosteroids (ICS) ± long acting 
bronchodilators (LABs) ± oral steroids. Patients using low to medium dose ICS ± LABs experienced relatively better 
survival. Also, male gender was associated with all-cause mortality in all patients (HR = 1.72, 95% CI 1.65-1.80) and 
especially in those in the highest pharmacotherapy level group (HR = 1.97, 95%CI = 1.84-2.10). The P-value of 
interaction between gender and pharmacotherapy level for the effect on all-cause death was significant (0.0003).
Conclusions: Older patients with CRD not using ICS experienced the worst survival in this study and may benefit from 
an escalation in therapeutic regime. Males had a higher risk of death than females, which was more pronounced in the 
highest pharmacotherapy level group. Hence, primary health care should more actively direct disease management to 
mild-to-moderate disease patients.
Background
Asthma and Chronic Obstructive Pulmonary Disease
(COPD) account for 80% of the total burden of chronic
respiratory diseases (CRD) in Australia [1] and represent
a significant burden to the Australian health care system
[2,3]. They are nevertheless under-diagnosed among the
older population because of atypical presentation and co-
morbidity [2,4,5]. These diseases have similar manifesta-
tions in older patients - wheezing, chest tightness and
shortness of breath - despite very different causes [6,7].
The estimated prevalence of asthma in Australian adults
over 15 years of age ranges from 10 to 12% [3], whereas
approximately 9-12% of Australians over 45 years have
symptomatic COPD [8,9].
The effects of patient demographic and clinical charac-
teristics on mortality in the general population is well
established [10]. For example, being a male, of indigenous
race, of low socio-economic status (SES) or living in a
remote area has been shown to increase the risk of dying
from any cause [10]. However, relatively few studies have
examined the risk factors for mortality in older patients
(≥ 65) with asthma [11,12]. Also, the risk factors for mor-
tality in older COPD patients have mainly been explored
in patients who have been hospitalised for COPD [13,14].
This is perhaps surprising given relatively high preva-
lence of asthma and COPD, an ageing population demo-
graphic and substantial health care costs resulting from
primary and secondary care of patients with these condi-
tions [8,15,16]. Further, the effects of patient characteris-
tics on mortality and how these effects differ according to
pharmacotherapy level remains uncertain.
Treatment with inhaled corticosteroids (ICS) is the cor-
nerstone of CRD management [17,18] despite that large
randomly controlled trials have had difficulty in estab-
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l is h i n g  a  be n e f i ci a l  e f f ect  o f  IC S  o n  s u rvi va l  i n  CO P D
patients [19]. Since distinguishing asthma and COPD in
older patients with CRD is often challenging due to sub-
stantial overlap both in clinical manifestations and in the
approach to disease management [6,7], studying the ben-
efit of ICS on survival in older CRD patients overall
remains important. We thus aimed to investigate (a) sur-
vival by pharmacotherapy level and (b) the effects of
patient gender, race, SES, and residential remoteness on
mortality due to any cause, overall as well as within
groups of differing pharmacotherapy level, in older CRD
patients in Western Australia (WA) during 1992-2006.
Methods
Data Sources
This study drew data from whole-population, de-identi-
fied hospital separation, mortality, pharmaceutical and
medical claims databases linked and accessed through
the Cross-Jurisdictional Linkage Facility of the WA Data
Linkage System (WADLS) maintained by the WA
Department of Health. The WADLS was established in
1995 and uses computerised probabilistic matching to
link over 30 administrative health databases [20]. Match-
ing procedures are based on full name and address, pho-
netic compression algorithms and other identifiers. An
evaluation of the WADLS linkage has shown that the
extensive matching procedures are 99.89% accurate [20].
We extracted linked data for WA residents aged at least
65 years between 1st January 1992 and 31st December
2006 from the Hospital Morbidity Data System (HMDS),
the Death Registry, the Electoral Roll, the Medicare Bene-
fits Scheme (MBS), and the Pharmaceutical Benefits
Scheme (PBS). The HMDS data included principal and
secondary diagnoses and procedures; and dates and types
of admissions and separations. The Death Registry data
included date and cause of death. The MBS data included
dates and types of services provided by medical practitio-
ners that qualified for Medicare benefits [21]. The PBS
data included date of supply and type of medication pre-
scribed. Registration information from the Electoral Roll
was also extracted to ascertain inward and outward
migration of the study population. Electoral Roll registra-
tion is compulsory for all Australian citizens residing in
Australia who have reached 18 years of age.
Study Population
Data records from the HMDS database, the death regis-
try, MBS and PBS, for people who were at least 65 years
o f  a g e  a t  t h e  t i m e  o f  r e c o r d  e n t r y ,  w e r e  c o m b i n e d  t o
ascertain the study population. We used the HMDS and
death data to identify individuals with a diagnosis or
death record of asthma, COPD or emphysema (ICD-9-
CM: 492-493.92, 496, 975.7, E945.7; ICD-10-AM: J43-J46,
T48.6, Y55.6) and bronchitis (ICD-9-CM: 491-491.21,
491.8-491.9; ICD-10-AM: J41-J42). The MBS data were
used to identify individuals undergoing a special asthma
management plan in general practitioner (GP) offices
(asthma cycle of care) subsidised by the government
(items 2546-2559 and 2664-2677). From the PBS data, a
list of the most commonly used asthma/COPD medica-
tion in Australia was used to identify potential asthma/
COPD patients. The drugs included beclomethasone,
budesonide, fluticasone, eformoterol, salmeterol, terbuta-
line, salbutamol, ipratropium, tiotropium, nedocromil,
theophylline and aminophylline. After combining these
records, 116,983 individuals were identified having a
HMDS, death, MBS and/or PBS asthma or COPD record.
Individuals with acute bronchitis were excluded by
removing all individuals with a bronchitis diagnosis or
death record if they did not have any other record of an
asthma or COPD-related diagnosis, treatment plan or
medication (n = 386). We then excluded individuals who
were not registered on the WA Electoral Roll during the
study period (n = 8285). All other individuals were
included in the study as asthma or COPD patients (n =
108,312). We refer to these conditions collectively as
'chronic respiratory diseases' (CRD) since they account
for the majority of the CRD burden in Australia [1].
A clinical consensus panel comprising seven general
practitioners, two geriatricians and three clinical phar-
macists was convened to develop guidelines for classifica-
tion of pharmacotherapy level (Table 1). If a patient had
been dispensed a combination of medications from dif-
ferent levels, the patient would be assigned the level
reflecting the highest pharmacotherapy ever given.
We used the Index of Relative Socio-Economic Disad-
vantage (IRD) to divide the study population into quin-
tiles of SES disadvantage based on areas of residence. The
variables used to compose the IRD are low income, low
educational attainment and high unemployment and are
collected as part of the Australian Census conducted
every five years [22]. To describe geographical disadvan-
tage, we used the Accessibility/Remoteness Index of Aus-
tralia (ARIA +), which measures access in terms of
physical distance from services and is grouped into five
categories: major cities, inner regional, outer regional,
remote, and very remote [23].
The study was approved by the Human Research Ethics
Committees of The University of Western Australia and
the WA Department of Health. It also conformed with
the principles of the Declaration of Helsinki.
Statistical Analyses
Patient follow-up began from the date of the first identi-
fied CRD record, start date of continuous Electoral Roll
registration, or 1st January 1992, whichever came last.
Follow-up ended at the date of the last record of any of
the HMDS/MBS/PBS databases, end date of the continu-Einarsdóttir et al. BMC Public Health 2010, 10:385
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ous Electoral Roll registration, date of death, or 31st
December 2006, whichever came first. We applied Cox
proportional hazards models to calculate hazard ratios
and 95% confidence intervals overall and by pharmaco-
therapy level. All models were adjusted for gender, age at
start of follow-up, indigenous status, socio-economic sta-
tus, residential remoteness, and Charlson index of co-
morbidity [24]. We assessed the proportional hazards
assumption for each covariate in each model and found
no evidence against proportionality. We used Cox pro-
portional hazards regression to estimate separate survival
curves for each pharmacotherapy level with death due to
any cause as outcome. The survival curves were adjusted
for all variables mentioned above by using in the model
the average value of each of the adjusting variables (mean
of covariates method). All analyses were performed using
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Patient Characteristics
Of the 108,312 CRD patients in our study, 72% were
selected on the basis of having had one or more CRD
medication prescription, 3% were selected on the basis of
a CRD hospital admission, 0.03% of having attended
'asthma cycle of care' GP services and 25% on the basis of
having records from various combinations of the four
datasets. Hence, the vast majority of our CRD patient
cohort (97%) had been prescribed a CRD medication at
least once.
Table 2 shows the characteristics of the 108,312
patients identified with CRD in our study, overall and by
pharmacotherapy level. We observed 9,943 deaths during
the 15 years of follow-up (average 6 years) with the
majority being in the highest pharmacotherapy level
group. The mortality rate was highest in the lowest
(1,827.1 per 100,000 PY) and highest (1,826.3 per 100,000
PY) pharmacotherapy level groups. Mean age at start of
follow-up in the whole group of patients was 72.7 years
(SD 7.0), and was fairly constant across pharmacotherapy
levels. Our study population was comprised of a slightly
higher proportion of females than males (53.1 vs. 46.9%)
and a relatively low proportion of indigenous patients
(0.6%).
All-cause Mortality
Figure 1 shows adjusted survival curves for all-cause
mortality in patients with CRD by pharmacotherapy
level. Patients in the lowest and highest pharmacotherapy
level groups exhibited relatively poor survival throughout
the follow-up period, where 79.5% and 79.7%, respec-
tively, were still alive at the end of follow-up. However,
patients in the low to medium pharmacotherapy level
groups had better survival with a slightly more gradual
decline than the patients in the other two groups (82.5%
and 84.6% still alive at the end of follow-up, respectively).
These differences in survival between the four pharmaco-
therapy levels were statistically significant (overall p <
0.0001). Adjusted hazard ratios for the effect of low to
Table 1: Pharmacotherapy levels for CRD based on medication dose as defined by a clinical consensus panel
SABs Low dose ICS * Medium dose ICS ± LABs * High dose ICS ± LABs ± OS *
Terbutaline AND/OR < 250 μg Beclomethasone AND/OR 250-500 μg Beclomethasone AND/
OR
> 500 μg Beclomethasone AND/OR
Salbutamol AND/OR < 400 μg Budesonide AND/OR 400-800 μg Budesonide AND/OR > 800 μg Budesonide AND/OR
Ipratropium AND/OR < 250 μg Fluticasone 250-500 μg Fluticasone > 500 μg Fluticasone
Tiotropium AND/OR
Nedocromil AND/OR
Eformoterol AND/OR Eformoterol AND/OR
Salmeterol Salmeterol
AND/OR
> 1 prescription per year of 
Hydrocortisone and/or Prednisolone
SABs = Short Acting Bronchodilators
ICS = Inhaled Corticosteroids
LABs = Long Acting Bronchodilators
OS = Oral Steriods
* Doses represent daily dosesEinarsdóttir et al. BMC Public Health 2010, 10:385
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high pharmacotherapy level on all-cause death compared
with the lowest level (short acting bronchodilators
(SABs)) were 0.82 (95% CI 0.76-0.90) for low dose ICS;
0.72 (95% CI 0.68-0.76) for medium dose ICS ± long act-
ing bronchodilators (LABs); and 0.94 (95% CI 0.89-0.99)
for high dose ICS ± LABs ± oral steroids (OS).
We assessed the likelihood of death due to any cause in
relation to patient characteristics, overall and by pharma-
cotherapy level (Table 3). Males were at increased risk of
all-cause death compared with females (HR 1.72, 95% CI
1.65-1.80). The estimates were modified by pharmaco-
therapy level, being highest in the highest pharmacother-
apy level group (HR 1.97, 95% CI 1.84-2.10). The P-value
for interaction between pharmacotherapy level and gen-
der for the effect on all-cause death was significant
(0.0003). Indigenous patients were more likely to die than
non-indigenous patients overall (HR 1.28, 95% CI 0.94-
1.73) and in the lowest, medium and high pharmacother-
apy level groups, but none of the hazard ratios was signif-
icant. Patients living in the most disadvantaged areas
were at increased likelihood of death compared with
patients in the least disadvantaged areas (HR 1.16, 95% CI
1.08 - 1.24). This association appeared to be higher in the
medium pharmacotherapy level group (HR 1.25, 95% CI
1.09 -1.42), but the test for interaction was not significant
(P = 0.1161). Residential remoteness did not appear to
affect the risk of death overall and by pharmacotherapy
level, with all hazard ratios being mostly weak and consis-
tent with chance variation.
Discussion
We investigated the effect of patient characteristics on
mortality in patients aged ≥ 65 years with CRD in WA,
overall and by pharmacotherapy level. Our main findings
included a relatively unfavourable survival of patients
using only SABS (i.e. in the lowest pharmacotherapy level
group), who experienced a slightly worse survival than
the highest pharmacotherapy level group. We also found
an increased likelihood of all-cause mortality in males
particularly if they were in the highest pharmacotherapy
level group.
A strength of this study was its whole-population
design. We used data that were routinely collected by the
WA and Commonwealth governments to ascertain
patients with CRD. The accuracy of the WA administra-
tive data and the record links produced by the WADLS
has been found to be exceptionally high [20]. However, as
the data were collected for administrative purposes
rather than research purposes, some consideration is
Table 2: Characteristics of older patients with CRD in WA 1992-2006, overall and by pharmacotherapy level
Patient Characteristic All patients SABs Low dose ICS Medium dose 
ICS ± LABs
High dose ICS ± LABs ± OS
Number of patients 108,312 29,700 9,378 37,085 32,149
Average years of follow-up 6.0 4.6 6.3 6.1 7.1
Person-years of follow-up 652,273.0 136,498.5 59,041.5 227,039.4 229,693.6
Number of deaths at the end of follow-up 9,943 2,494 823 2,432 4,194
Mortality rate (per 100,000 person-years) 1,524.4 1,827.1 1,393.9 1,071.2 1,826.3
Mean age at start of follow-up 72.7 ± 7.0 74.7 ± 7.6 72.7 ± 6.8 71.4 ± 6.4 72.3 ± 6.7
SABs = Short Acting Bronchodilators
ICS = Inhaled Corticosteroids
LABs = Long Acting Bronchodilators
OS = Oral Steriod
Figure 1 Adjusted survival curves for all-cause mortality in pa-
tients with CRD by pharmacotherapy level. Curves are adjusted for 
gender, age start of follow-up, area-based socio-economic status, resi-
dential remoteness, the Charlson index of co-morbidity, and indige-
nous status. SABs = Short Acting Bronchodilators, ICS = Inhaled 
Corticosteroids, LABs = Long Acting Bronchodilators, OS = Oral Steri-
ods.E
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Table 3: Association between characteristics of CRD patients and risk of death, overall and by pharmacotherapy level
Patient Characteristic All patients SABs Low dose ICS Medium dose ICS ± LABs High dose ICS ± LABs ± OS P-value for interaction
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Gender*
Female 1.00 1.00 1.00 1.00 1.00
Male 1.72 (1.65-1.80) 1.53 (1.40-1.67) 1.56 (1.35-1.82) 1.64 (1.50-1.79) 1.97 (1.84-2.10) 0.0003
Race*
Non-Indigenous 1.00 1.00 1.00 1.00 1.00
Indigenous 1.28 (0.94-1.73) 1.38 (0.79-2.42) 1.06 (0.25-4.58) 1.36 (0.70-2.65) 1.18 (0.74-1.87) 0.8841
Socioeconomic status quintile*
L e a s t  d i s a d v a n t a g e d 1 . 0 01 . 0 01 . 0 01 . 0 0 1 . 0 0
2nd least disadvantaged 1.03 (0.96-1.10) 1.03 (0.90-1.17) 1.03 (0.81-1.31) 0.99 (0.87-1.14) 1.04 (0.93-1.15) 0.8144
Medium disadvantaged 1.05 (0.98-1.12) 0.99 (0.86-1.13) 1.03 (0.82-1.31) 1.05 (0.91-1.20) 1.07 (0.96-1.19) 0.5340
2nd most disadvantaged 1.06 (0.99-1.14) 0.97 (0.85-1.12) 1.20 (0.96-1.51) 1.06 (0.93-1.22) 1.07 (0.96-1.19) 0.7491
Most disadvantaged 1.16 (1.08-1.24) 1.00 (0.87-1.15) 1.14 (0.91-1.44) 1.25 (1.09-1.42) 1.19 (1.07-1.31) 0.1161
Residential remoteness*
Major Cities 1.00 1.00 1.00 1.00 1.00
Inner Regional 0.95 (0.89-1.01) 1.00 (0.88-1.15) 1.04 (0.83-1.32) 0.99 (0.87-1.13) 0.87 (0.79-0.97) 0.2424
Outer Regional 1.00 (0.92-1.07) 1.06 (0.91-1.23) 1.00 (0.76-1.32) 0.97 (0.84-1.13) 0.97 (0.87-1.09) 0.5563
Remote 0.83 (0.70-0.99) 0.88 (0.61-1.26) 0.58 (0.24-1.41) 1.09 (0.81-1.45) 0.70 (0.54-0.90) 0.4457
Very Remote 0.87 (0.58-1.30) 0.49 (0.18-1.36) 0.62 (0.08-4.79) 1.13 (0.56-2.28) 1.01 (0.56-1.84) 0.1967
* Adjusted for Charlson index of co-morbidity and all other variables in the table using Cox multivariate regression.
HR = hazard ratio; 95% CI = 95% confidence interval; SABs = Short Acting Bronchodilators; ICS = Inhaled Corticosteroids; LABs = Long Acting Bronchodilators; OS = Oral SteriodEinarsdóttir et al. BMC Public Health 2010, 10:385
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warranted of the inherent limitations in patient ascertain-
ment. First, our CRD study population included everyone
at least 65 years old who had ever had a CRD medication
dispensed during a 15 year period and thus the majority
of our patient sample was selected on the basis of having
had a CRD medication dispensed. This case ascertain-
ment strategy appeared to overestimate the cases of CRD.
However, based on data analysed by our group from 12
general practices in WA that included diagnostic infor-
mation, out of 23,850 asthma/COPD prescriptions pre-
scribed by general practitioners, 92% had asthma and/or
COPD as reason for visit or prescription (unpublished
data) This result indicates a strong correlation between
CRD prescribing practice in WA and CRD diagnosis.
Also, out of the 72% of patients selected in our study
based on CRD medication use only, 30% were selected
based on one single prescription. The majority of these
30%, or 56%, were within the SABs only pharmacotherapy
level, which by definition includes patients more likely to
require only occational treatment with medications. Thus
the majority of our study population had established pat-
terns of medication use indicative of a CRD problem.
Consequently, by using this selection strategy we can be
reasonably confident that with considerable specificity
we have included all CRD cases in the older WA popula-
tion who have ever seen a doctor for breathing problems.
Furthermore, when we restricted our analyses to the
patients who were selected based on medication use only
and to patients selected based on records from all data-
sets we found the results led to essentially the same con-
clusions. It is therefore unlikely that the ascertainment
strategy had any meaningful impact on our results.
A second consideration relates to the fact that the PBS
data consisted only of records of dispensed drugs that
were subsidised by the scheme. The vast majority of Aus-
tralians over 65 years of age are eligible to receive a gov-
ernment concession card, entitling then to receive large
PBS and MBS subsidies on medicines and other services.
The coverage by these cards in 2004-5 was 90% at ages
65-75 and 95% at ages 75 + years [25]. We expect that the
coverage of older people with CRD has been even higher
than this. We thus believe it is safe to assume that a very
high proportion of CRD patients in this study were con-
cessional beneficiaries. Hence, this would likely have had
no more than limited impact on our study since all
inhaled corticosteroids and long-acting beta agonist
medications were subsidised under the PBS, and inhaled
short-acting beta agonist medications and oral corticos-
teroids were consistently subsidised for concessional ben-
eficiaries [26]. Another issue concerning the use of PBS
records in this study is that it is possible to buy inhaled
SABs 'over the counter' from pharmacies in WA, which
may make the findings of worse survival in the lowest
pharmacotherapy level to appear to be due to less access
t o  c a r e .  H o w e v e r ,  t h e  v a s t  m a j o r i t y  o f  p a t i e n t s  i n  t h e
study would have been concessional beneficiaries. Thus
seeing a doctor was free from out-of-pocket expense and
there were strong financial incentives for the patients to
buy SABs using a doctor's prescription instead of over the
counter. In addition, the findings were adjusted for socio-
demographic and locational disadvantage. We thus
believe that access to care is an unlikely explanation for
our findings.
The third possible limitation in this study concerns the
inclusion of COPD patients with a mild disease in the
highest pharmacotherapy level group. Exacerbations
from COPD can occur at any severity and COPD patients
may therefore be prescribed oral corticosteroids sporadi-
cally at any level of severity. We believe this would not
have caused a problem in our study since we included in
the highest pharmacotherapy level group those patients
who were taking oral corticosteroids at a regular basis,
using the criterion: > 1 prescription per year of oral ste-
roids. Furthermore, despite exclusive oral steroid users
being 51% of the patients in the highest pharmacotherapy
level group; after excluding those users from this group,
the results from our study remained unaltered.
The final limitation relates to the fact that we were
unable to obtain data on smoking exposure in the
patients. Smoking is a confounder in this study because it
affects mortality in asthma/COPD as well being associ-
ated with the patient characteristics. The State and Com-
monwealth do not collect reliable data on smoking
exposure as part of their routine administrative data sets.
However, all our results were adjusted for factors such as
socio-economic status, residential remoteness, gender,
indigenous status, and co-morbidity, which most likely
removed the majority of the confounding due to smoking.
We examined the survival outcomes of patients in our
study according their level of pharmacotherapy and
found that those using only SABs experienced the worst
survival. This relatively unfavourable survival of patients
not using ICS might reflect sub-optimal treatment in at
least a sub-group of patients in this category [4,27-32].
That is, some patients in this group could benefit from an
escalation of their therapeutic regime including the addi-
tion of ICS. This main finding of this manuscript is par-
ticularly interesting given the fact that large randomly
controlled trials have had difficulty in establishing a bene-
ficial effect of ICS on survival in COPD patients [19].
We observed that males were almost twice as likely to
die from any cause than females. These findings accord
with previous studies of older asthma patients [11,12,16]
as well as reports on the general population [10]. Further,
our results indicate that the poorer survival of males was
more marked in the highest pharmacotherapy level
group. This may have reflected the tendency of men to
seek medical care at a later stage in the disease processEinarsdóttir et al. BMC Public Health 2010, 10:385
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than women [10,33]. In fact, despite that women with
asthma or COPD account for the majority of emergency
department (ED) visits and hospitalisations for asthma
[34-39] as well as a large proportion of hospitalisations
for COPD [40], women who present to the ED have been
found to receive more outpatient care and to have better
pulmonary function than men [34]. Hospitalised women
with asthma have also been reported to experience less
severe asthma than men [35], evidenced by the higher
incidence of ED intubation of male respiratory patients
[41].
We detected a relatively low proportion of indigenous
patients in our study (0.6%), which was only slightly lower
than the proportion of indigenous individuals among
Western Australians aged 65+ years (0.8%) [42]. Indige-
nous Australians experience significantly decreased life-
expectancy and far higher mortality than other Austra-
lians [10]. This was evident in our study of older patients
with CRD, although the hazard ratio was not statistically
significant, which may be due to small numbers. How-
ever, our results most likely reflect the persisting gap in
access to adequate primary health care that indigenous
people are faced with in Australia [43]. For reasons such
as cost, distance and lack of transport, indigenous people
do not always seek medical assistance when needed [43].
This can mean that any existing disease is more likely to
become severe.
Conclusions
We studied the effect of patient characteristics on all-
cause mortality in older patients with CRD, overall and by
pharmacotherapy level. We found that patients using only
SABs experienced the worst survival. These results indi-
cate that some patients with CRD not currently using ICS
could possibly benefit from enhancements to their thera-
peutic regime, but further research is warranted for cor-
roboration. We also found that increased likelihood of
all-cause mortality in males was more pronounced if they
were in the highest pharmacotherapy level group. Collec-
tively, these findings illustrate the importance of more
actively focusing disease management on mild-to-moder-
ate CRD. This has been emphasized by Cranston et al.,
who suggest that a more fruitful primary care approach is
needed for managing mild-to-moderate CRD in Australia
since most guidelines are based on moderate-to-severe
disease [44]. Our findings are thus important for primary
health care policy because they highlight a need to more
actively target services at patients with mild-to-moderate
CRD so as to prevent disease progression and subsequent
mortality.
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